View Clinical Trial (Medical Research Study)

A Study of Pemetrexed, Carboplatin and Bevacizumab in Patients With Nonsquamous Non-Small Cell Lung Cancer - NCT00762034-53226(Clinical Trial 243871)



ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.


Signup
City:  Milwaukee
State:  
WI
Zip Code: 53226
Conditions: Non-small Cell Lung Cancer
Purpose: This study will compare overall survival in patients with Stage IIIB or IV nonsquamous non-small cell lung cancer.
Study summary:
Criteria: Inclusion Criteria: - You must sign an informed consent document for clinical research. - You must have Stage IIIB or Stage IV nonsquamous non-small cell lung cancer. - You must not have received any prior treatment for your disease. - Prior radiation therapy is allowed to < 25% of the bone marrow; however, prior radiation to the whole pelvis is not allowed. If you have had radiation therapy to the chest, you are not eligible to participate. - You must be at least 18 years of age or older. - You must have measureable tumor lesions according to the Response Evaluation Criteria in Solid Tumors (RECIST) or disease can be evaluated on CT scan. - Your test results assessing the function of blood forming tissue, kidneys and liver must be satisfactory. - Women must be sterile, postmenopausal or on contraception and men must be sterile (e.g. post-vasectomy) or on contraception. Exclusion Criteria: - You cannot have clinically significant third-space fluid collections (e.g. ascites or pleural effusions that cannot be controlled by drainage or other procedures). - You cannot have NSCLC of predominantly squamous cell histology. - You cannot have known central nervous system (CNS) disease, other than stable, treated brain metastasis. - You cannot have undergone a surgical procedure, open biopsy, open pleurodesis, or significant traumatic injury within 28 days of starting the study treatment, or have an anticipated need for major surgery during the study. - You cannot have a history of gastrointestinal fistula, perforation, or abscess, inflammatory bowel disease, or diverticulitis. - You are currently receiving ongoing treatment with full-dose warfarin or equivalent. - You cannot have significant vascular disease, serious cardiac conditions (such as heart attack), stroke or transient ischemic attack within 6 months of the trial. - You cannot have evidence of bleeding diathesis or coagulopathy (in the absence of therapeutic anticoagulation). - You cannot have inadequately controlled hypertension, or a history of hypertensive crisis or hypertensive encephalopathy. - You cannot have a serious, nonhealing wound, active ulcer, or untreated bone fracture. - You cannot have another form of cancer, other than superficial basal cell and superficial squamous (skin) cell, or carcinoma in situ of the cervix within the last 5 years. - You cannot have received an investigational treatment within 30 days prior to the trial. - You cannot have previously received treatment with paclitaxel, carboplatin, pemetrexed, or bevacizumab. - You cannot be pregnant or breast-feeding. - You cannot have a known sensitivity to any component of paclitaxel, carboplatin, pemetrexed, or bevacizumab. - You cannot have a history of hemoptysis (coughing blood) within 3 months prior to the trial. - You are unable to stop taking aspirin more than 1.3 grams per day or other nonsteroidal anti-inflammatory drugs (NSAIDs). - You are unable or unwilling to take folic acid or vitamin B12 supplementation. - You are unable to take corticosteroids. - You have any other on-going illnesses including active infections that may not allow you to adhere to the requirements of the trial.
Study is available at: For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Milwaukee, WI 53226
United States

Primary Contact:
There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559)
Phone: 1-317-615-4559
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
Trials Alerts: If you would like to be notified of new clinical trials as they become available please register for a free account.
Data Source: ClinicalTrials.gov
Date Processed: March 22, 2011
Modifications to
this listing:		 Only selected fields are shown, please use the link above to view all information about this clinical trial.